Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (1521-1530 of 1,779) with videos related to

Pageof 178
Sort By:
Mabs|September 3, 2013
Inhibition of angiogenesis by a novel neutralizing antibody targeting human VEGFR-3Hao Chen, Xiuyun Ding, Yuan Gao, et al.
Mabs|August 9, 2013
Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industryAlain Beck, Janice M Reichert
Mabs|August 9, 2013
From Bretonneau to therapeutic antibodies, from specificity to specific remedies, Saint-Cyr-Sur-Loire, France, November 19, 2012Claire Marchand, Romaric Nouat, Hervé Watier
Mabs|August 9, 2013
Elongation of the C-terminal domain of an anti-amyloid β single-chain variable fragment increases its thermodynamic stability and decreases its aggregation tendencyGeovanny Rivera-Hernández, Marta Marin-Argany, Bernat Blasco-Moreno, et al.
Mabs|December 30, 2015
A human monoclonal antibody against small envelope protein of hepatitis B virus with potent neutralization effectWei Wang, Lina Sun, Tiansheng Li, et al.
Mabs|January 14, 2016
Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacyYun Yang, Qingcheng Guo, Xi Chen, et al.
Mabs|January 14, 2016
Full validation of therapeutic antibody sequences by middle-up mass measurements and middle-down protein sequencingAnja Resemann, Wolfgang Jabs, Anja Wiechmann, et al.
Mabs|August 8, 2015
Specific in vivo knockdown of protein function by intrabodiesAndrea L J Marschall, Stefan Dübel, Thomas Böldicke
Mabs|August 8, 2015
Antibody humanization by structure-based computational protein designYoonjoo Choi, Casey Hua, Charles L Sentman, et al.
Mabs|October 31, 2015
Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumabFabienne Courtois, Neeraj J Agrawal, Timothy M Lauer, et al.
Pageof 178

Showing results (1521-1530 of 1,779) with videos related to

Sort By:
Pageof 178
Mabs|September 3, 2013
Inhibition of angiogenesis by a novel neutralizing antibody targeting human VEGFR-3Hao Chen, Xiuyun Ding, Yuan Gao, et al.
Mabs|August 9, 2013
Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industryAlain Beck, Janice M Reichert
Mabs|August 9, 2013
From Bretonneau to therapeutic antibodies, from specificity to specific remedies, Saint-Cyr-Sur-Loire, France, November 19, 2012Claire Marchand, Romaric Nouat, Hervé Watier
Mabs|August 9, 2013
Elongation of the C-terminal domain of an anti-amyloid β single-chain variable fragment increases its thermodynamic stability and decreases its aggregation tendencyGeovanny Rivera-Hernández, Marta Marin-Argany, Bernat Blasco-Moreno, et al.
Mabs|December 30, 2015
A human monoclonal antibody against small envelope protein of hepatitis B virus with potent neutralization effectWei Wang, Lina Sun, Tiansheng Li, et al.
Mabs|January 14, 2016
Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacyYun Yang, Qingcheng Guo, Xi Chen, et al.
Mabs|January 14, 2016
Full validation of therapeutic antibody sequences by middle-up mass measurements and middle-down protein sequencingAnja Resemann, Wolfgang Jabs, Anja Wiechmann, et al.
Mabs|August 8, 2015
Specific in vivo knockdown of protein function by intrabodiesAndrea L J Marschall, Stefan Dübel, Thomas Böldicke
Mabs|August 8, 2015
Antibody humanization by structure-based computational protein designYoonjoo Choi, Casey Hua, Charles L Sentman, et al.
Mabs|October 31, 2015
Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumabFabienne Courtois, Neeraj J Agrawal, Timothy M Lauer, et al.
Pageof 178